Purpose: Different modalities of radiation therapy nowadays allow for effective treatment of uveal melanoma combined with the advantage of eye preservation. However, this advantage can secondarily be impaired by radiation-related side effects. After local recurrence, secondary glaucoma (SG) has been described as second most frequent complication leading to need of enucleation. This study compares the incidence of SG after conventional Ruthenium (Ru)-106 brachytherapy (BT) versus CyberKnife robotic radiosurgery (RRS) which has been gaining importance lately as an efficient treatment option offering improved patient comfort. Methods: Medical records of all patients diagnosed with uveal melanoma in the Eye Clinic of the Ludwig-Maximilians-University Munich between 2007 and 2013 were reviewed. A total of 268 eyes of 268 patients treated with Ru-106 BT or CyberKnife-RRS as monotherapy were entered in this retrospective cohort study. Incidence of SG was correlated with treatment modality and baseline tumour characteristics. Results: Fifty-three patients (19.8%) developed SG. At 5 years, SG was significantly more frequent after RRS (46.7%) than BT (11.1%); however, tumour thickness (maximum apical height) as a marker of tumour progress was more pronounced in the RRS group. Subgroup analysis of 178 patients for tumours amenable to both BT and RRS (thickness ≤6 mm) revealed comparable results at 3 years (RRS: 13.8 versus BT: 11.2%), but a trend towards increased incidence after RRS beyond year three. However, this difference was not significant at 5 years (28.2% versus 11.2%, p = 0.138). Tumour thickness was significantly associated with incidence of SG. Conclusion: In tumours ≤6 mm thickness, RRS and BT seem to offer a comparable safety profile in terms of SG. Beyond year three, SG was tendentially, but not significantly more frequent after RRS. Increasing tumour thickness is associated with risk of SG.
Introduction
Combining state-of-the-art survival rates with the advantage of eye preservation, radiation-based treatments have become the first choice for uveal melanoma (Lommatzsch et al. 2000; DienerWest et al. 2001; Damato et al. 2005; Muacevic et al. 2008; Modorati et al. 2009; Eibl-Lindner et al. 2016) . Among these, brachytherapy (BT) is widely used as first-line treatment for smaller tumours (Margo 2004) . Medium and large tumours are preferably treated by charged particle external radiotherapy, mainly proton beam (Damato et al. 2005) or conventional stereotactic irradiation (Zehetmayer et al. 1999; Dieckmann et al. 2001) and, more frequently, robotic radiosurgery (RRS) (Muacevic et al. 2008; Modorati et al. 2009; EiblLindner et al. 2016) . In recent times, RRS has been increasingly gaining importance as it combines good results in the treatment of all sizes of tumours with a couple of advantages over conventional external radiotherapy (EiblLindner et al. 2016) . Whereas stereotactic applications and proton beam therapy require multiple treatment sessions and often hospitalization, RRS provides more patient comfort as it can be applied on a single day. Moreover, it is less invasive as it does not depend on strict fixation of the eye via stereotactic frames or suturing of rectus muscles (Modorati et al. 2009; Sarici & Pazarli 2013) . Currently, CyberKnife (Accuray, Sunnyvale, CA, USA) is the most accurate and advanced clinically available form of RRS and has become available worldwide in an increasing number of specialized centres (Hara et al. 2007; Kaul et al. 2015) .
Results of radiation therapy for uveal melanoma can secondarily be impaired by radiation-related side effects (Brown et al. 1982; Packer et al. 1992; Margo 2004; Klingenstein et al. 2013) . Among these, secondary glaucoma (SG) has been reported as one of the most frequent and severe findings (Packer et al. 1992; Puusaari et al. 2004; Muacevic et al. 2008; Eibl-Lindner et al. 2016) . It seriously diminishes quality of life (Klingenstein et al. 2013) and has been shown to be the most frequent reason along with local recurrence for need of secondary enucleation (Shields et al. 1989; van den Bosch et al. 2015) . Currently, no data comparing BT and RRS in terms of risk of SG are available. Therefore, this study examines incidence and risk factors for SG in 268 patients treated with either RRS or BT for uveal melanoma.
Patients and Methods
Medical records of all patients diagnosed with uveal melanoma in the Eye Clinic of the Ludwig-Maximilians-University Munich between 2007 and 2013 were reviewed with approval of the Institutional Review Board. Patients with glaucoma/intraocular pressure (IOP) ≥21 mmHg prior to radiation treatment, in need of a second treatment due to tumour recurrence or follow-up <6 months, were excluded from analysis.
Patients were thoroughly informed about the advantages and disadvantages of BT and RRS treatment concerning efficacy, safety and all required medical procedures. Brachytherapy (BT) was performed in 99 patients for tumours with a thickness ≤6 mm and a tumour base length of <19 mm, and in one patient with a thickness of 6.1 mm on personal request. In 168 patients, RRS was indicated because BT was not possible due to tumour thickness >6 mm or localization within 3.0 mm to the macula or optic disc. Due to the advantages of a single-session treatment and avoidance of surgical interventions, some patients, in whom both treatment modalities were feasible, chose RRS over BT on personal preference even though BT was recommended as first-line treatment.
As alternative, all patients were offered proton beam irradiation off-site and primary enucleation, however excluded from analysis if doing so. Robotic radiosurgery (RRS) was performed on the CyberKnife system (Accuray Inc., Sunnyvale, California, USA) as described elsewhere (Muacevic et al. 2008; Eibl-Lindner et al. 2016) , delivering a median dose of 20 Gray (Gy) in a single fraction. Brachytherapy was performed with episceral radioactive Ruthenium (RT)-106 plaques as described elsewhere (Lommatzsch et al. 2000) , applying 100 Gy to the tumour apex for 2-7 days. Ophthalmological follow-up examinations were scheduled after 3, 6, 12 and 18 months and annually after that. Oncological follow-up care included hepatic sonography and laboratory tests twice a year and additional CT/MRI scans, if needed.
Medical records were screened for documentation of radiation retinopathy, neovascularization of the iris, IOP ≥21 mmHg (with date of first diagnosis), start of IOP-lowering medication, painless amaurosis and need of enucleation. Secondary glaucoma (SG) following radiation therapy was defined as following: (i) IOP >21 mmHg with therapeutic consequence (i.e. start of IOP-lowering medication on the same day or enucleation within 2 weeks); (ii) IOP >21 mmHg without need of therapy because of painless amaurosis; (iii) presentation with not previously documented IOP-lowering medication prescribed elsewhere. Incidence of SG was compared between RRS and BT within the whole cohort and for patients with a tumour thickness ≤6 mm. Additionally, risk factors including tumour thickness and reflectivity, ciliary body/ iris involvement and tumour localization were correlated with diagnosis of glaucoma.
Statistical analysis was performed in SPSS Statistics 23 (SPSS Inc., Chicago, IL, USA). Metric parameters between both treatment groups were compared using a two-tailed Student's t-test with a 95% confidence interval (95% CI); a Mann-Whitney U-test was used for comparison of localization. Incidence of NVG was assessed with KaplanMeier estimates, compensating for loss to follow-up. Influence of potential risk factors was evaluated with a Chisquare test and Pearson correlation. Multivariate analysis of risk factors for SG was performed with Cox regression. Significance was defined as p < 0.05.
Results
Of 424 cases of uveal melanoma, application of exclusion criteria allowed for inclusion of 268 eyes of 268 patients. 62.7% (168) of these were treated with RRS, 37.3% (100) with Ru-106 BT.
Mean follow-up for RRS was 28.9 AE 17.0 months and 39.8 AE 24.7 months for BT. Baseline patient characteristics can be found in Table 1 . Robotic radiosurgery (RRS) and BT treatment groups did not differ in mean age at diagnosis, sex or localization of the affected eye (p > 0.05 for all comparisons).
Baseline tumour characteristics can be found in Table 2 . Preradiation mean tumour thickness was significantly higher (p < 0.001) in the RRS (6.5 AE 3.0 mm) than the BT (4.0 AE 1.0 mm) group. Maximum thickness was 15.8 mm for RRS versus 6.1 mm for BT. Preradiation reflectivity showed significantly lower values in the RRS than the BT group (p = 0.046). Reflectivity was negatively correlated with tumour size (Pearson correlation: r = À0.508; p < 0.001). In both groups, tumours were most frequently found in middle periphery; tumours involving the posterior pole showed a tendency to be more frequent in the RRS than the BT group, however, without significance (p = 0.086). Ciliary body involvement was similar in RRSand BT-treated peripheral tumours (p = 0.345). Of 268 patients, 72 (26.9%) developed radiation retinopathy and 57 (21.3%) visible iris neovascularization (Table 3) . Incidence of radiation retinopathy was similar for RRS and BT treatment at 5 years (p = 0.056, Table 3 ). Iris neovascularization was significantly more frequent after RRS (30.6%) than BT (5.3%) treatment (p < 0.001, Table 3 ).
Fifty-three patients (19.8%) developed SG as defined in our study. In 51 patients, IOP >21 mmHg was diagnosed during follow-up, resulting in start of treatment in all but two (painless amaurosis). Two patients presented with IOP-lowering medication prescribed elsewhere during follow-up.
Incidence of SG differed significantly (p < 0.001) between both treatment groups with 46.7% after RRS versus 11.1% after BT (Fig. 1) . There was no significant difference in mean time until onset of glaucoma (p = 0.407; RRS: 20.1 AE 13.5 months; BT: 15.1 AE 10.9 months) and mean increase in IOP in both groups (p = 0.147; RRS: 35.0 AE 10.4 mmHg; BT: 28.4 AE 5.2). However, maximum measured IOP was higher in RRS than in BT (60 versus 40 mmHg). 56.6% of patients with SG had iris neovascularization visible without additional gonioscopy. Time of first diagnosis of SG and iris neovascularization correlated strongly (r = 0.827; p < 0.001).
As 79 of 168 patients (47%) treated with RRS and 99 of 100 (99%) treated with BT had a maximum tumour thickness of ≤6 mm, a total of 178 patients were eligible for subgroup analysis. In this cohort, mean tumour thickness did not differ significantly (p = 0.654) for RRS (3.9 mm) and BT (4.0 mm). Comparable incidence of SG was seen at 3 years (RRS: 13.8% versus BT: 11.2%); however, beyond that, incidence was tendentially more pronounced after RRS. At 5 years, 28.2% of patients developed SG after RRS, as opposed to 11.2% after BT. However, this difference was not statistically significant (p = 0.138, Fig. 1 ).
Tumour thickness was strongly associated with incidence of SG (p < 0.001 for all comparisons; Fig. 2) . No significant correlation was found for tumour reflectivity (p = 0.348), tumour localization (p = 0.717) or ciliary body involvement (p = 0.698).
Multivariate Cox regression proved these findings. Tumour thickness showed strong association (p < 0.001; hazard ratio: 1.303; 95% confidence interval: 1.151-1.475). No correlation was found for treatment modality (p = 0.152), tumour reflectivity (p = 0.491), ciliary body involvement (p = 0.531) or tumour localization (p = 0.521).
Mean follow-up after first diagnosis of SG in all 53 patients was 16.0 AE 14.7 months. In 27 of 53 (50.9%) patients, local and systemic IOP-lowering therapy allowed for sufficient management. Up to 39 mmHg upon first presentation, local medication was applied if not contraindicated, with dorzolamide, timolol and brimonidine as substances of first choice. In some cases, additional prostaglandines were also used, however, only if signs of inflammation (e.g. radiation retinopathy) were absent. In refractory cases and above 40 mmHg, carbonic anhydrase inhibitors, preferably acetazolamide (500 mg), were used intravenously. If IOP could not be sufficiently regulated with topic medication only in the long term, invasive treatments were scheduled and patients received peroralacetazolamide (250 mg) until then. Nine patients (17%) needed laser treatment [cyclophotocoagulation (CPC) or YAG-iridotomy]. In two patients (3.8%), filtrating surgery was performed. In 13 patients (24.5%), however, enucleation could not be avoided. Two patients (3.8%) did not need any therapy because of painless amaurosis.
Of 268 patients, data on visual acuity (VA) at last visit were available in 267. Patients were graded into low vision as defined by the WHO (<20/63) and visual function better than low vision (≥20/63). Visual acuity (VA) strongly correlated with the absence of SG (Fig. 2) : VA ≥20/63 was preserved in 39.3% of patients without SG, as opposed to only 7.5% with SG (p < 0.001; Fig. 3 ). 
Discussion
Choice of treatment modality for uveal melanoma primarily relies on local tumour control and overall survival. As BT and RRS offer equally good outcome herein (Diener-West et al. 2001; Muacevic et al. 2008; Macdonald et al. 2011; Eibl-Lindner et al. 2016) , secondary measures, especially treatment-related complications, are crucial to critical appraisal of each radiation modality. Robust evidence on occurrence of SG after BT exists (Summanen et al. 1996; Shields et al. 2002; Sagoo et al. 2014) , but only few studies concerning CyberKnife-RRS with limited patient numbers are available (Muacevic et al. 2008; Zorlu et al. 2009 ). Additionally, these studies for BT and RRS are difficult to compare as they use different definitions of SG (e.g. IOP >23 or >25 mmHg). To the best of our knowledge, this is the first large direct comparison of incidence of SG after BT versus RRS for uveal melanoma. In our study, elevated IOP was defined as >21 mmHg. While this value is acknowledged for glaucoma as a chronic disease, some other studies have used higher cut-offs in case of radiationrelated glaucoma [e.g. 23 or 24 mmHg (Summanen et al. 1996; Puusaari et al. 2004) ]. Nevertheless, 96% of patients diagnosed with SG in our study had to face therapeutic consequences ranging from topical medication to need of enucleation, which can represent a major burden for the patient.
When comparing incidence for all 268 patients, SG was significantly more frequent after RRS than BT. The 11.1% we found 5 years after BT correlate well with previous evidence. A cohort with very similar characteristics as in our study was described by Krause (2015) who reported 12.4% after 5 years for 843 patients exclusively treated with Ru-106 BT with a comparable mean thickness of 4.8 AE 1.7 mm. Summanen et al. (1996) have described 19% for a cohort with a mean thickness of 6 mm exclusively treated with Ru-106 BT; Shields et al. 2002) found 21%, however, mean thickness was higher (9 mm) and different radiation sources were used . These two studies already suggest that higher tumour thickness may be associated with increased incidence of SG.
After RRS, our data indicate an incidence of SG of 46.7% at 5 years. Comparable evidence has been described in previous literature, for example Klingenstein et al. (2013) with 33%. However, even if our data show a significantly higher incidence of SG after RRS, careful interpretation is needed. While both groups were comparable in terms of patient-related risk factors, for example age (Zehetmayer et al. 2000; Mishra et al. 2013) , tumour characteristics differed significantly. Especially tumour thickness as proven important risk factor for SG (Zehetmayer et al. 2000; Mishra et al. 2013; van den Bosch et al. 2015) was significantly more pronounced in the RRS Fig. 1 . Kaplan-Meier comparison of incidence of secondary glaucoma after robotic radiosurgery versus brachytherapy in (A) all patients and (B) patients with a tumor prominence ≤6 mm. group and might have acted as a confounder. While tumours >6 mm were only seen in 1% in BT, this cohort made up 53% of patients treated with RRS. In all 268 patients, 21.1% of patients with a thickness <3 mm, but in contrast, 72.8% of patients >9 mm developed SG. Multivariate analysis proved this correlation; every increase in thickness of a Millimetre resulted in a hazard ratio of 1.303 for development of SG. We hypothesize that on the one hand, this can be explained by increasing thickness correlating with larger tumour volume. This requires higher cumulative dosage which increases risk of radiation retinopathy, destruction of vascular plexus and hypoxia, which in turn induce secretion of pro-angiogenic factors, especially vascular endothelial growth factor (VEGF), driving neovascular obstruction of the iridocorneal angle (Tripathi et al. 1998) . On the other hand, toxic tumour syndrome is more frequent in large lesions and has been described as separate pathomechanism of glaucoma after tumour irradiation due to release of cellular debris and pigment (Kiratli & Bilgic 2004; Damato et al. 2013) .
External radiotherapy is the first-line treatment for tumours either above 6 mm thickness or in close proximity of the macula or optic nerve head. With BT, it becomes difficult to apply sufficient radiation doses to the tumour while sparing healthy tissue when thickness increases; and towards the posterior pole, plaque placing becomes increasingly challenging (Quivey et al. 1996) . In contrast, patients with a tumour thickness ≤6 mm are eligible for both BT and external radiotherapy. Nowadays, many patients prefer external radiotherapy as surgical procedures can often be avoided, and from a clinical perspective, a meta-analysis by Wang et al. (2013) hints at better rates of local control especially for proton beam therapy compared to conventional BT.
Currently, CyberKnife-RRS irradiation presents one of the most advanced forms of radiosurgery (Hara et al. 2007; Kaul et al. 2015) and has been widely established for many indications as it can be applied in a more convenient, time-/cost-efficient and less invasive fashion (Eibl-Lindner et al. 2016) compared to conventional stereotactic modalities. Especially for patients eligible for both RRS and BT, data on incidence and severity of secondary complications are crucial when obtaining informed consent. In this context, our study provides first evidence that, in addition to comparable primary outcome, both treatment methods also offer similar results in incidence of SG for tumours ≤6 mm. This was especially true at 3 years, while beyond that -in contrast to steady results after BT -incidence of SG continued to increase after RRS, even if no statistically significant difference between RRS and BT was seen at 5 years. This might be partially explained by the lower number of patients completing year five follow-up compared to year three, but further investigation into long-term risk factors for SG after RRS is warranted. No difference in severity of SG, measured as mean IOP, was found between both groups. This is especially important for clinical practice: in about 50% of our patients with SG, local or intravenous administration of IOPlowering medication did not allow for sufficient management. Need of surgery and especially of enucleation, which affected almost every fourth patient with SG, represent a major burden for the already critically ill.
Calculating radiation-related risk factors for SG, irradiation of the ciliary body and posterior pole have been described as crucial (Langmann et al. 2000; Hirasawa et al. 2007; Mishra et al. 2013) . Rather strikingly, in our study, none of these two were associated with SG. This may be due to the fact that according to local practice, these are classified as highrisk tumours. In these cases, RRS is preferred because of its higher accuracy, allowing for more efficient sparing of these pivotal structures. Indeed, RRS showed a higher percentage of tumours localized in close proximity to the ciliary body or optic nerve head than BT. Reversely, this may indicate that in spite of a selection of tumours at greater risk, RRS provides noninferior outcome in terms of SG, adding further evidence towards safety in the treatment of localizations not amenable to BT.
First signs of SG were seen after a median 16-18 months; previous data hint at a latency of 10-21 months (Mueller et al. 2000; Muacevic et al. 2008) . With a mean follow-up of 29 and 40 months for BT and RRS, respectively, we believe our analysis has detected most of the cases of SG. However, additional longer observations are needed for definite evidence.
Concludingly, in addition to similar rates of local control, RRS and BT offer a comparable safety profile in terms of incidence of SG for tumours amenable to both radiation modalities. This is of great importance for eye retention as primary rationale for radiation therapy of uveal melanoma, as local recurrence and SG together make up approximately 82-90% of reasons for secondary enucleation (Macdonald Bosch et al. 2015; Fabian et al. 2015; Eibl-Lindner et al. 2016 ). However, long-term follow-up screening for late manifestations of SG after RRS seems necessary.
